Agencies are dedicating more time and staff to digital accessibility efforts, but acquisition is still a key hurdle when it comes to Section 508 compliance.
Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating tumor DNA (ctDNA) testing in the National ...